UMN study provides new insight into use of cell replacement therapies to treat muscular dystrophies
(University of Minnesota Medical School) The University of Minnesota Medical School continues its legacy of advancing cell replacement therapies with a scientific breakthrough that highlights the promise of cell therapies for muscular dystrophy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 13, 2019 Category: International Medicine & Public Health Source Type: news

URMC Designated as a Duchenne Care Center
Parent Project Muscular Dystrophy, a nonprofit organization dedicated to advancing care and research for patients with Duchenne muscular dystrophy, has named the University of Rochester Medical Center a Certified Duchenne Care Center. This program of leading centers, created in 2014 by PPMD, reviews and recognizes clinics nationwide for their outstanding neuromuscular programs. (Source: University of Rochester Medical Center Press Releases)
Source: University of Rochester Medical Center Press Releases - February 12, 2019 Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news

New research insights hold promise for kids with DMD
(Children's National Health System) Prednisone, the current standard of care used to treat kids with Duchenne muscular dystrophy (DMD), reduces chronic inflammation but has harsh side effects. Eplerenone, a heart failure drug, is used in older patients to treat cardiomyopathy, a leading cause of mortality for people with DMD. A new medicine under development appears to combine the beneficial effects of these drugs for the heart and muscle while also showing improved safety in experimental models. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 11, 2019 Category: International Medicine & Public Health Source Type: news

Discovery points to innovative new way to treat Duchenne muscular dystrophy
(The Ottawa Hospital) Researchers at The Ottawa Hospital and the University of Ottawa have discovered a new way to treat the loss of muscle function caused by Duchenne muscular dystrophy in animal models of the disease. As reported in Cell Stem Cell, the team restored muscle stem cell function that is impaired in Duchenne muscular dystrophy, resulting in efficient regeneration of the muscle and preventing the progressive loss of muscle strength characteristic of the disease. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - January 31, 2019 Category: International Medicine & Public Health Source Type: news

Medical News Today: ALS: A new therapy may be in sight
New research, led by Harvard scientists, identifies a novel potential therapeutic target for treating amyotrophic lateral sclerosis (ALS). (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 17, 2019 Category: Consumer Health News Tags: Muscular Dystrophy / ALS Source Type: news

Muscle stem cells can drive cancer that arises in Duchenne muscular dystrophy
People with Duchenne muscular dystrophy (DMD) can develop an otherwise-rare muscle cancer, called rhabdomyosarcoma, due to the muscle cells' continuous work to rebuild the damaged tissue. However, little is known about how the cancer arises, hindering development of a treatment or test that could predict cancer risk. (Source: World Pharma News)
Source: World Pharma News - January 15, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Muscle stem cells can drive cancer that arises in Duchenne muscular dystrophy
(Sanford Burnham Prebys Medical Discovery Institute) Scientists from Sanford Burnham Prebys Medical Discovery Institute (SBP) have demonstrated that muscle stem cells may give rise to rhabdomyosarcoma that occurs during DMD--and identified two genes linked to the tumor's growth. The research, performed using a mouse model of severe DMD, helps scientists better understand how rhabdomyosarcoma develops in DMD--and indicates that ongoing efforts to develop treatments that stimulate muscle stem cells should consider potential cancer risk. The study was published in Cell Reports on January 15, 2019. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 15, 2019 Category: Cancer & Oncology Source Type: news

Researchers overcome hurdle in CRISPR gene editing for muscular dystrophy
(University of Missouri-Columbia) The gene editing technique known as CRISPR is a revolutionary approach to treating inherited diseases. However, the tool has yet to be used to effectively treat long-term, chronic conditions. A research team led by Dongsheng Duan, PhD, at the University of Missouri School of Medicine has identified and overcome a barrier in CRISPR gene editing that may lay the foundation for sustained treatments using the technique. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 8, 2019 Category: International Medicine & Public Health Source Type: news

Home Monitoring of Lung Function Feasible in Teens With Duchenne
MONDAY, Jan. 7, 2019 -- In adolescent patients with Duchenne muscular dystrophy (DMD), use of a handheld device (HHD) to assess pulmonary function at home is feasible and provides reliable data, according to an analysis recently published in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 7, 2019 Category: Pharmaceuticals Source Type: news

An Experimental Procedure Could Help More Families Have Healthy Babies. But It ’s Not Allowed in the U.S.
When Noah Shulman was born a few days after Christmas 2016, his parents Kristelle and Evan had no reason to worry about him. The pregnancy went smoothly, and so did the birth. But within a few days of taking his first breath, Noah began to struggle. He wasn’t feeding, so he started losing weight. He was also lethargic. Several pediatricians reassured the Shulmans that they were probably just overly sensitive to Noah’s symptoms because Kristelle is a nurse and Evan is a physician assistant–a case of first-time-parent-white-coat syndrome. “They kind of dismissed us as neurotic parents,” says Eva...
Source: TIME: Science - January 3, 2019 Category: Science Authors: Alice Park Tags: Uncategorized fertility Research Source Type: news

An Experimental Procedure Could Help More Families Have Healthy Babies. But It ’s Not Allowed in the U.S.
When Noah Shulman was born a few days after Christmas 2016, his parents Kristelle and Evan had no reason to worry about him. The pregnancy went smoothly, and so did the birth. But within a few days of taking his first breath, Noah began to struggle. He wasn’t feeding, so he started losing weight. He was also lethargic. Several pediatricians reassured the Shulmans that they were probably just overly sensitive to Noah’s symptoms because Kristelle is a nurse and Evan is a physician assistant–a case of first-time-parent-white-coat syndrome. “They kind of dismissed us as neurotic parents,” says Eva...
Source: TIME: Health - January 3, 2019 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized fertility Research Source Type: news

U.S. Drug Developer Capricor Places Duchenne Drug Trial on Hold U.S. Drug Developer Capricor Places Duchenne Drug Trial on Hold
Capricor Therapeutics Inc said on Wednesday it had put on hold a clinical trial of its drug to treat Duchenne muscular dystrophy (DMD), a muscle-wasting disorder, citing a safety review.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 27, 2018 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

Company halts drug trial for rare disease
Capricor Therapeutics has announced that it is stopping progress on a trial for a new Duchenne muscular dystrophy treatment. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - December 27, 2018 Category: Pharmaceuticals Source Type: news

U.S. drug developer Capricor places Duchenne drug trial on hold
Capricor Therapeutics Inc said on Wednesday it had put on hold a clinical trial of its drug to treat Duchenne muscular dystrophy (DMD), a muscle-wasting disorder, citing a safety review. (Source: Reuters: Health)
Source: Reuters: Health - December 26, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Capricor places Duchenne drug trial on hold
Capricor Therapeutics Inc said on Wednesday it had put on hold a clinical trial of its drug to treat Duchenne muscular dystrophy, a muscle-wasting disorder. (Source: Reuters: Health)
Source: Reuters: Health - December 26, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Golodirsen (SRP-4053) in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53
CAMBRIDGE, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, announced today that it has completed the submission of its rolling New Drug Application (NDA)... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 20, 2018 Category: Drugs & Pharmacology Source Type: news

Monitoring lung function at home in teens with Duchenne muscular dystrophy
(IOS Press) Heart and lung complications are responsible for much of the morbidity and mortality associated with Duchenne muscular dystrophy (DMD). Although regular monitoring of pulmonary function is recommended in order to detect deterioration, compliance with routine testing, such as hospital-based spirometry, is frequently poor. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 17, 2018 Category: International Medicine & Public Health Source Type: news

New mouse model may speed identification of promising muscular dystrophy therapies
(Massachusetts General Hospital) A Massachusetts General Hospital research team has created a new mouse model of a common form of muscular dystrophy with the potential of rapidly distinguishing promising therapeutic drugs from those unlikely to be successful. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 12, 2018 Category: International Medicine & Public Health Source Type: news

UMN researchers give new insight to muscular dystrophy patients
(University of Minnesota Medical School) New research by University of Minnesota scientists has revealed the three dimensional structure of the DUX4 protein, which is responsible for the disease, facioscapulohumeral muscular dystrophy (FSHD). Unlike the majority of genetic diseases, FSHD is not caused by a protein that is missing or not functioning properly. Rather it is caused when a functioning, normal, protein shows up in a place where it doesn't belong (in muscles). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 12, 2018 Category: International Medicine & Public Health Source Type: news

Newly published model of FSHD and a potential gene therapy to improve functional outcomes
(Nationwide Children's Hospital) Facioscapulohumeral muscular dystrophy (FSHD) is the most prevalent dominantly inherited muscular dystrophy in the world. To date, there are no pharmacologic treatments available for the more than 850,000 people affected worldwide. Developing models to use for testing potential therapeutics has been a challenge for the research community. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 16, 2018 Category: International Medicine & Public Health Source Type: news

Improved Mobility With Metformin in Myotonic Dystrophy Type 1 Improved Mobility With Metformin in Myotonic Dystrophy Type 1
This Phase II RCT showed promise for metformin for improving the mobility of patients with myotonic dystrophy type 1, the most common form of muscular dystrophy in adults.Brain (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 14, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

Moths and magnets could save lives
(Rice University) Rice University bioengineers have combined a virus that infects moths with magnetic nanoparticles to create a potential new therapy for inherited genetic diseases like muscular dystrophy, sickle cell, cystic fibrosis, spinal muscular atrophy and some forms of cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 13, 2018 Category: Cancer & Oncology Source Type: news

Life-changing intersection between big data and therapeutic pipeline in neuromuscular disease
(MWW Group) A new report funded by the Muscular Dystrophy Association (MDA) and released by the IQVIA Institute for Human Data Science indicates that genetic testing and breakthrough therapies will transform the diagnosis and care of neuromuscular disease within the next decade. The report, 'Understanding Neuromuscular Disease Care,' highlights current gaps in care and opportunities to optimize care and accelerate the emergence of new therapies. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 30, 2018 Category: International Medicine & Public Health Source Type: news

Sarepta CEO charts path forward on Duchenne drug amid stock slide
Sarepta has seen its share price decline in the wake of data from a small study of its gene therapy drug for Duchenne muscular dystrophy. But the Cambridge biotech is moving forward with its clinical trial work and expansion plans. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 11, 2018 Category: Pharmaceuticals Authors: Allison DeAngelis Source Type: news

Glucose-derived dietary supplement increases muscle-force production in Duchenne muscular dystrophy
(Natural News) According to a study, a dietary supplement extracted from glucose can help boost muscle-force production. Researchers involved in the study believe this can one day help patients with Duchenne muscular dystrophy (DMD). The study, which involved researchers from Université Laval’s Faculty of Medicine and Centre hospitalier universitaire (CHU) de Québec Research Centre-Université Laval, was published in the... (Source: NaturalNews.com)
Source: NaturalNews.com - October 8, 2018 Category: Consumer Health News Source Type: news

Medical News Today: How can gold help repair muscle injuries?
In a new and innovative study, researchers have found that gold nanoparticles attached to anti-inflammatory agents can work to promote muscle regeneration. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 5, 2018 Category: Consumer Health News Tags: Muscular Dystrophy / ALS Source Type: news

Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy
Mutations in the gene encoding dystrophin, a protein that maintains muscle integrity and function, cause Duchenne muscular dystrophy (DMD). The deltaE50-MD dog model of DMD harbors a mutation corresponding to a mutational "hotspot" in the human DMD gene. We used adeno-associated viruses to deliver CRISPR gene editing components to four dogs and examined dystrophin protein expression 6 weeks after intramuscular delivery (n = 2) or 8 weeks after systemic delivery (n = 2). After systemic delivery in skeletal muscle, dystrophin was restored to levels ranging from 3 to 90% of normal, depending on muscle type. In cardi...
Source: ScienceNOW - October 4, 2018 Category: Science Authors: Amoasii, L., Hildyard, J. C. W., Li, H., Sanchez-Ortiz, E., Mireault, A., Caballero, D., Harron, R., Stathopoulou, T.-R., Massey, C., Shelton, J. M., Bassel-Duby, R., Piercy, R. J., Olson, E. N. Tags: Medicine, Diseases, Molecular Biology reports Source Type: news

Gene editing and muscular dystrophy
(Source: ScienceNOW)
Source: ScienceNOW - October 4, 2018 Category: Science Authors: Kiberstis, P. A. Tags: Medicine, Diseases, Molecular Biology twis Source Type: news

Sarepta Gene Therapy Appears To Help Fourth Boy With Duchenne Muscular Dystrophy
“The cautionary note is this all has to be confirmed in a larger trial,” says Douglas Ingram, Sarepta’s president and chief executive. “Our goal is to bring this therapy rapidly to patients around the world,” Ingram says. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 3, 2018 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Source Type: news

Weekly Postings
See something of interest? Please share our postings with colleagues in your institutions! Spotlight September is National Preparedness Month. Disasters Happen. Prepare Now. Learn How. This week: Learn Life Saving Skills. Member Highlights: Let us shine a spotlight on the amazing work you do! NNLM MAR is always interested in learning about health outreach projects and activities that are happening in Pennsylvania, New York, New Jersey and Delaware. Share your story with us to receive a Member Highlight on the MARquee! National Network of Libraries of Medicine News Funding Available: NNLM MAR has funding available for ...
Source: NN/LM Middle Atlantic Region Blog - September 14, 2018 Category: Databases & Libraries Authors: Hannah Sinemus Tags: Weekly Postings Source Type: news

Duchenne muscular dystrophy: How muscle cells journey to the dark side
(Sanford Burnham Prebys Medical Discovery Institute) Answers to treating muscular dystrophies could lie in better understanding muscle repair--which resembles a delicate cellular dance choreographed by special cells called fibro-adipogenic progenitors (FAPs). Now, scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) have revealed that FAPs don't have just one identity--but several distinct identities that emerge during key stages of muscle regeneration. These cells they could be targeted for drug development. The study was published in Nature Communications. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 11, 2018 Category: International Medicine & Public Health Source Type: news

Insuring patient access and affordability for treatments for rare and ultra-rare diseases
(American College of Medical Genetics and Genomics) The last decade has seen tremendous progress in the development of new drugs for patients with genetic disorders, including Cystic Fibrosis, many lysosomal storage disorders (Gaucher disease, Fabry disease and others) and most recently, Duchenne Muscular Dystrophy and Spinal Muscular Atrophy (SMA). The American College of Medical Genetics and Genomics (ACMG) is concerned with the staggering projected cost of these new treatments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 7, 2018 Category: International Medicine & Public Health Source Type: news

ARMGO Pharma Receives FDA Orphan Drug Designation for ARM210/S48168 for the Treatment of Ryanodine Receptor Type 1 Related Myopathies
ARDSLEY, N.Y., Sept. 5, 2018 -- (Healthcare Sales & Marketing Network) -- ARMGO Pharma, Inc., a clinical stage biopharmaceutical company advancing a novel class of small molecule drugs known as Rycals®, announced today that the U.S. Food and Drug Admi... Biopharmaceuticals, FDA ARMGO Pharma, Rycals, Duchenne Muscular Dystrophy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 5, 2018 Category: Pharmaceuticals Source Type: news

Pfizer terminates domagrozumab (PF-06252616) clinical studies for the treatment of Duchenne muscular dystrophy
Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD): a Phase 2 safety and efficacy study (B5161002) and an open-label extension study (B5161004). (Source: World Pharma News)
Source: World Pharma News - September 5, 2018 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Breakthrough in muscular dystrophy research after scientists edit DNA to rebuild muscles
Researchers from the University of Texas managed to use DNA editing to treat dogs with Duchenne muscular dystrophy and hope to begin trials in humans within the next few years. (Source: the Mail online | Health)
Source: the Mail online | Health - August 31, 2018 Category: Consumer Health News Source Type: news

CRISPR Treatment for Duchenne Muscular Dystrophy Helps Dogs
Researchers boosted levels of the dystrophin protein to nearly normal levels in a canine model of the disease. (Source: The Scientist)
Source: The Scientist - August 31, 2018 Category: Science Tags: News & Opinion Source Type: news

Pfizer halts Duchenne research
Pfizer is ending two ongoing clinical studies for a Duchenne muscular dystrophy drug after determining that the evidence " did not support a significant treatment effect. ” (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - August 30, 2018 Category: Pharmaceuticals Source Type: news

Pfizer halts Duchenne trials
Pfizer is ending two ongoing clinical studies for a Duchenne muscular dystrophy drug after determining that the evidence " did not support a significant treatment effect. ” (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - August 30, 2018 Category: Pharmaceuticals Source Type: news

CRISPR Gene Editing Fixes Muscular Dystrophy in Dogs. Are Humans Next?
The powerful gene editing technology CRISPR is one small step closer to treating a human disease. In a new paper published in Science, researchers led by Eric Olson, professor and chair of molecular biology at UT Southwestern Medical Center, reported that he and his team successfully used CRISPR to correct the genetic defect responsible for Duchenne muscular dystrophy in four beagles bred with the disease-causing gene. It’s the first use of CRISPR to treat muscular dystrophy in a large animal. (Previous studies had tested the technology on rodents.) In varying degrees, the genetic therapy halted the muscle degradatio...
Source: TIME: Health - August 30, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Genetics healthytime Source Type: news

Gene-editing hope for muscular dystrophy
The technique was used to restore a protein that people with the condition are unable to make. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - August 30, 2018 Category: Consumer Health News Source Type: news

Doctors hail breakthrough in muscular dystrophy treatment
Researchers use experimental gene-editing procedure to correct dystrophin gene mutations in dogsDoctors in the US have raised hopes of a treatment for muscular dystrophy, the most common fatal genetic condition in children, after mending mutations that cause the disease in dogs.The landmark study is the first to claim success at treating the muscle wasting disorder in large mammals, though scientists on the team caution that more work lies ahead to ensure the procedure is safe and effective for use in people.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - August 30, 2018 Category: Science Authors: Ian Sample Science editor Tags: Medical research Science Genetics Source Type: news

Infographic: Treating Duchenne Muscular Dystrophy with CRISPR
The disease is caused by mutations in a single gene. Can gene editing fix the problem? (Source: The Scientist)
Source: The Scientist - August 30, 2018 Category: Science Tags: Infographics Source Type: news

Gene'Editing' in Dog Study Shows Promise for Kids With Muscular Dystrophy
THURSDAY, Aug. 30, 2018 -- For the first time, scientists report using gene-editing technology to halt the progression of muscular dystrophy in dogs -- suggesting a possible breakthrough for children with a form of the disease. Reporting in the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 30, 2018 Category: General Medicine Source Type: news

Inch by inch, towards a treatment for Duchenne muscular dystrophy
(American Association for the Advancement of Science) Researchers using CRISPR genome editing in a large animal model have boosted expression of the dystrophin gene to levels that could be therapeutic in humans, they say. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - August 30, 2018 Category: Infectious Diseases Source Type: news

Inhibiting NF- & #954;B improves heart function in a mouse model of Duchenne muscular dystrophy
(Medical University of South Carolina) In an August 24, 2018 article in Nature Communications, investigators at the Medical University of South Carolina and Ohio State University report that nuclear factor kappa B (NF-κB) down-regulates calcium genes, contributing to cardiomyopathy in Duchenne muscular dystrophy (DMD). Murine data show cardiomyocyte ablation of NF-κB rescues cardiac function. NF-κB promotes global chromatin landscape changes that repress calcium mobilization in DMD. This mechanism also contributes to skeletal muscle dysfunction. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 30, 2018 Category: International Medicine & Public Health Source Type: news

In dogs, CRISPR fixes a muscular dystrophy
(Source: ScienceNOW)
Source: ScienceNOW - August 30, 2018 Category: Science Authors: Cohen, J. Tags: Biotechnology, Medicine, Diseases, Molecular Biology In Depth Source Type: news

New CRISPR technique skips over portions of genes that can cause disease
(University of Illinois at Urbana-Champaign) In a new study in cells, University of Illinois researchers have adapted CRISPR gene-editing technology to cause the cell's internal machinery to skip over a small portion of a gene when transcribing it into a template for protein building. Such targeted editing could one day be useful for treating genetic diseases caused by mutations in the genome, such as Duchenne's muscular dystrophy, Huntington's disease or some cancers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 16, 2018 Category: International Medicine & Public Health Source Type: news

This matrix delivers healing stem cells to injured elderly muscles
(Georgia Institute of Technology) Muscles of the elderly and of patients with Duchene muscular dystrophy have trouble regenerating. A new nanohydrogel with muscle stem cells has boosted muscle growth in mouse models while protecting the stem cells from immune reactions that usually weaken or destroy them. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 15, 2018 Category: International Medicine & Public Health Source Type: news

A protein could be key to preserving heart function in Duchenne muscular dystrophy
(American Heart Association) The brain-derived neurotrophic factor protein, known to be vital for brain function, might hold the key for preserving heart function in children and young adults with Duchenne muscular dystrophy.Heart failure often kills Duchenne patients early in life and there is no effective treatment.Developing therapies designed to activate or supplement brain-derived neurotrophic factor could give new hope to patients at risk for Duchenne cardiomyopathy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 1, 2018 Category: International Medicine & Public Health Source Type: news

Understanding muscular dystrophy and home remedies to help manage it
(Natural News) Muscular dystrophy is a group of genetic diseases wherein the skeletal muscles weaken and break down over time. This condition is brought on by the absence of dystrophin, an essential protein that plays an important role in normal muscle function. People who lack dystrophin will often have difficulty swallowing and moving, and will... (Source: NaturalNews.com)
Source: NaturalNews.com - July 28, 2018 Category: Consumer Health News Source Type: news